

Clinical Development Physician / Associate Medical Director

Unique opportunity to make an impact in a company that strives for becoming the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology

Y-mAbs is a fast-paced, growing company in the process of expanding its organization to support the continuous growth and the exciting clinical pipeline with activities in both early and late-stage clinical development.

To support this journey Y-mAbs is now looking for a Clinical Development Physician wishing to enter a clinical development role, or an Associate Medical Director with existing experience in clinical development or clinical trials in oncology who is seeking to expand their experience and responsibilities.

As Clinical Development Physician or Associate Medical Director at Y-mAbs, you will join an experienced and dynamic Medical team consisting of Medical Directors in clinical development, Clinical Drug Safety, Pharmacovigilance and US Medical Affairs. Together, they support the clinical development, regulatory approval, scientific engagement and successful launch of medicines.

Both roles will report to senior Medical Directors covering the anti-GD2 (naxitamab) and anti-B7H3 (omburtamab) program.

Your main tasks are:

- Day-to-day medical oversight of ongoing clinical trials
- Involvment in the development of new protocols (line extensions)
- Analyse clinical data
- Oversee safety in collaboration with relevant colleauges
- · Participate in data monitoring committee meetings and data cleaning of clinical trial data
- Networking with international external experts, developing advocacy through credible scientific discussions

Furthermore, you will serve as an internal resource, collaborating with all functions, providing medical input, guidance and training. In addition, you will work across the other clinical programs where required, and support the responsible Medical Directors in overseeing the planning, execution and interpretation of clinical trials.

Your qualifications are preferably 3 years of experience in clinical development/operations or oncology. You have a strong teamwork attitude and are comfortable in working in cross-functional teams with medical, regulatory, saftety, data management and statistics. Your comunication and collaboration skills are excellent, and you speak and write English fluently.

A Master's Degree in medicine (MD or equivalent) is required, combined with experience from the industry.

You are a person with a can-do attitude and a positive and proactive approach. You have the ability to work independently with multiple tasks and under ambitious timelines. Furthermore, you have great analytical skills and eye for details and good planning and problem handling abilities.

It is an exciting time to join Y-mAbs, as they have just had their first FDA approval and launch of the flagship pediatric cancer drug - Naxitamab, and further have a promising pipeline of several new cancer medicines which are both in early and late stage of development. This role will give the right person extremely valuable experience in the development, approval and launch of such medicines, and an opportunity to broaden their knowledge across multiple disease areas and indications.

Travelling: 20-25 days per year.

Domicile: The role will be part of the Y-mAbs R&D Medical Department, based in the Y-mAbs Head Office in Hørsholm, Denmark.

Unique Human Capital is handling the recruitment. For more details about the job or the company, please contact CEO Jørn Duhn, Unique Human Capital on M: +45 21 75 19 25 or Research Consultant Jeanne Dederding, Unique Human Capital on M: +45 28 74 58 71. All applications must be submitted in English and are treated confidentially.

You can apply directly via this link:

https://uhc.dk/ledige-stillinger/clinical-development-physician-associate-medical-director/

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Their mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, they envision expanding their capabilities to treat adults - changing the course of cancer care and its outcomes. Currently, there are 100+ permanent employees in Y-mAbs.

Read more at www.ymabs.com.